Drug

Ripretinib clinical trials

Also written DCC-2618.

studies test it: 9
open now: 1
in phase 3: 3
first study started: 2015

How each study uses ripretinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ripretinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: 15 May 2020 · QINLOCK · NDA 213973 (FDA, Drugs@FDA)
European Union: 18 Nov 2021 · Qinlock · EMEA/H/C/005614 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ripretinib: 8

Brand

QINLOCK: 1

Development codes

DCC-2618: 6

Studies by the year they started

9 studies that test it; most in 2020 (2)

Studies that test ripretinib, by start year
Year	Studies
2015	1
2018	1
2019	1
2020	2
2021	2
2023	1
2026	1

By phase

A phase 1/2 study counts in both.

Phase 1: 4
Phase 2: 3
Phase 3: 3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Gastrointestinal Stromal Tumors: 8

Who runs them

Industry 9 · Other 0

Deciphera Pharmaceuticals, LLC (6) · Zai Lab (Shanghai) Co., Ltd. (2) · Ono Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Repaglinide (1) · Binimetinib (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Studies

Open first, then newest update. How each study uses ripretinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Given beside what is tested · 1 — ripretinib is usual care or a partner of the new treatment

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesActive, not recruitingPhase 1/2Deciphera Pharmaceuticals, LLCNCT05957367Written as Ripretinib

Codes

What other systems call ripretinib · ClinicalTrials.gg INT001343

MeSH (NLM) C000707850ripretinibConfirmed ClinicalTrials.gov, NLM
UNII (FDA) 9XW757O13DRIPRETINIBConfirmed FDA, NLM, Wikidata
RxNorm 2369389One source FDA
Wikidata Q27076996ripretinibConfirmed FDA, NLM, Wikidata
NCI Thesaurus C124067RipretinibOne source FDA
DrugBank DB14840One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C000707850	ripretinib	Confirmed ClinicalTrials.gov, NLM
UNII (FDA)	9XW757O13D	RIPRETINIB	Confirmed FDA, NLM, Wikidata
RxNorm	2369389	—	One source FDA
Wikidata	Q27076996	ripretinib	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C124067	Ripretinib	One source FDA
DrugBank	DB14840	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.